Identification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase by Torrie, Leah et al.
                                                                    
University of Dundee
Identification of inhibitors of an unconventional Trypanosoma brucei kinetochore
kinase
Torrie, Leah; Zuccotto, Fabio; Robinson, David; Gray, David; Gilbert, Ian; De Rycker, Manu
Published in:
PLoS ONE
DOI:
10.1371/journal.pone.0217828
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Torrie, L., Zuccotto, F., Robinson, D., Gray, D., Gilbert, I., & De Rycker, M. (2019). Identification of inhibitors of
an unconventional Trypanosoma brucei kinetochore kinase. PLoS ONE, 14(5), 1-16. [e0217828].
https://doi.org/10.1371/journal.pone.0217828
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 24. Dec. 2019
RESEARCH ARTICLE
Identification of inhibitors of an
unconventional Trypanosoma brucei
kinetochore kinase
Leah S. Torrie, Fabio Zuccotto, David A. Robinson, David W. Gray, Ian H. Gilbert*,
Manu De RyckerID*
Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of
Dundee, Dundee, United Kingdom
* I.H.Gilbert@dundee.ac.uk (IHG); M.DeRycker@dundee.ac.uk (MDR)
Abstract
The discovery of 20 unconventional kinetochore proteins in Trypanosoma brucei has
opened a new and interesting area of evolutionary research to study a biological process
previously thought to be highly conserved in all eukaryotes. In addition, the discovery of
novel proteins involved in a critical cellular process provides an opportunity to exploit differ-
ences between kinetoplastid and human kinetochore proteins to develop therapeutics for
diseases caused by kinetoplastid parasites. Consequently, we identified two of the uncon-
ventional kinetochore proteins as key targets (the highly related kinases KKT10 and
KKT19). Recombinant T. brucei KKT19 (TbKKT19) protein was produced, a peptide sub-
strate phosphorylated by TbKKT19 identified (KKLRRTLSVA), Michaelis constants for
KKLRRTLSVA and ATP were determined (179 μM and 102 μM respectively) and a robust
high-throughput compatible biochemical assay developed. This biochemical assay was vali-
dated pharmacologically with inhibition by staurosporine and hypothemycin (IC50 values of
288 nM and 65 nM respectively). Surprisingly, a subsequent high-throughput screen of a
kinase-relevant compound library (6,624 compounds) yielded few hits (8 hits; final hit rate
0.12%). The low hit rate observed was unusual for a kinase target, particularly when
screened against a compound library enriched with kinase hinge binding scaffolds. In an
attempt to understand the low hit rate a TbKKT19 homology model, based on human cdc2-
like kinase 1 (CLK1), was generated. Analysis of the TbKKT19 sequence and structure
revealed no obvious features that could explain the low hit rates. Further work will therefore
be necessary to explore this unique kinetochore kinase as well as to assess whether the few
hits identified can be developed into tool molecules or new drugs.
Introduction
Kinetochores are multiprotein complexes that associate with the centromere of a chromosome
during cell division, ensuring faithful transmission of genetic material to daughter cells [1, 2].
While kinetochores are evolutionary quite plastic, most eukaryotic kinetochores share the
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same canonical kinetochore machinery [3]. The kinetochores of the protozoan parasite Trypa-
nosoma brucei, the causative agent of human African trypanosomiasis [4], are an exception to
this. The discovery of 20 novel kinetochore proteins in T. brucei [5–7], with no detectable
homology to conventional eukaryotic kinetochore proteins, raises not only an interesting area
of research to investigate the evolutionary history of these proteins, but also the possibility of
exploiting these unique proteins in the search for new therapeutics, in particular as these pro-
teins are conserved across the kinetoplastida order. This includes Leishmania spp. and Trypa-
nosoma cruzi, the causative agents of leishmaniasis and Chagas disease [8, 9]. These neglected
and devastating diseases affect some of the world’s poorest populations with current drug
treatments suffering from high cost, host toxicity and emerging resistance [10, 11]. In the
search for new therapeutics for these diseases, targeting novel, but essential, enzymes within
the parasite provides an attractive start point for drug discovery. The finding that four of the
kinetoplastid kinetochore proteins (KKTs) are kinases offers an opportunity to exploit a
known, druggable enzyme family, whilst also targeting proteins unique to the parasite.
Of the four kinetochore kinases previously described [5, 6] (KKT2 (Tb927.11.10520), KKT3
(Tb927.9.10920), KKT10 (Tb927.11.12410) and KKT19 (Tb927.11.12420)), the KKT2 and
KKT3 proteins were found to be similar in terms of domain organisation and amino acid
sequence (48% similarity), as were the KKT10 and KKT19 proteins (also referred to as CLK1
and CLK2 respectively [12, 13]) (85% similarity), with these pairs most probably arising from
gene duplication events. Genome-wide RNAi studies in T. brucei reveal that knockdown of
these kinetochore kinases is associated with loss-of-fitness of the parasite [14, 15]. Further
studies confirm that knockdown of protein levels with either KKT2, KKT10 or dual KKT10 /
KKT19 RNAi constructs affect cell growth [5, 12, 13]. Interestingly, despite a genome-wide
RNAi screen showing loss-of-fitness when KKT19 alone is knocked down [14, 15], subsequent
KKT19 RNAi studies in T. brucei have revealed no effect on parasite growth [13, 16].
Chemical validation of the KKT10 protein has been achieved using the natural product
hypothemycin [13]. This compound was shown to inhibit both T. brucei KKT10 (TbKKT10 /
TbCLK1) activity (IC50 = 150 nM) and T. brucei cell growth (EC50 = 170 nM), with chemopro-
teomics confirming hypothemycin engages primarily with TbKKT10 in T. brucei cell lysates at
concentrations relevant to cellular efficacy [13]. Hypothemycin was also shown to reduce para-
sitemia in T. brucei infected mice, with prolonged survival of infected mice over 30 days and a
33% cure rate observed following 7 daily treatments with 10 mg/ml hypothemycin [13].
Based on these data, the KKT10 / KKT19 proteins were prioritised as targets for entry into a
kinetoplastid drug discovery program. These kinases have been classified as members of the
LAMMER subfamily of CMGC kinases [17] with 100% sequence identity in the active site. As
such, any inhibitors identified would be expected to inhibit both kinases which, as highlighted
in RNAi studies, confers a growth defect in T. brucei parasites [5]. Due to the successful pro-
duction of recombinant TbKKT19 protein, the current study focuses on the development of a
high-throughput screening assay for TbKKT19 and the subsequent high-throughput screen of
a kinase-relevant compound library to identify ATP site inhibitors of this unique kinetoplastid
kinetochore kinase.
Materials and methods
Protein expression and purification method for recombinant TbKKT19
A His-tagged, full-length TbKKT19 expression construct (kindly provided by Bungo
Akiyoshi) was transformed into Rosetta 2 competent cells for protein production. A 60 ml
overnight culture was set up and grown at 37˚C 200 rpm for 16 h and was used the next
day to inoculate 6 litres of LB+AMP+Kan media. Cells were grown at 37˚C until the
Trypanosoma brucei KKT19 inhibitors
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OD600 = 0.704 then induced with 0.2 mM ITPG then grown 20˚C for 16 hrs before harvest-
ing by centrifugation at 3,500 g for 30 min and storage at -20˚C. Lysis buffer (60 ml, 50 mM
NaPhosphate / 500 mM NaCl / 10% Glycerol / 20 mM Imidazole pH 7.5 / protease inhibitor
tablets / DNAase) was added and the pellets defrosted at 25˚C in a water bath for approxi-
mately 20 min. The slurry was then passed through a Cell Disrupter (Constant Systems) set at
30 KPSI to lyse the cells. The sample was then centrifuged at 40,000 g for 30 min. The super-
natant was then filtered using syringe filters to 0.2 μm. The supernatant was loaded onto a 5
ml HiTrap Ni HP column that had been equilibrated with Buffer A (50 mM NaPhosphate /
500 mM NaCl / 10% Glycerol / 20 mM Imidazole pH 7.5) at 5 ml/min using an AKTA Pure
(GE). Once loaded the column was washed with 10 column volumes of buffer A followed by
5% Buffer B (50 mM NaPhosphate / 500 mM NaCl / 10% Glycerol / 500 mM Imidazole pH
7.5) to wash off His-rich contaminating proteins. A linear gradient of 5–50% B was used to
elute the protein. Approximately 38 mg of protein (from 6 L culture) was present in the frac-
tions containing the TbKKT19 protein. The sample was then passed through a 0.2 μm filter,
before loading onto a XK26/60 Superdex 75 column using an AKTA Pure at Room Temp at 2
ml/min.
TbKKT19 substrate identification
Following production of recombinant protein, TbKKT19 was screened against a panel of 41
putative kinase peptide substrates (at a concentration of 300 μM or 100 μM for peptide
KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC) and 3 putative protein substrates
(at a concentration of 1 mg/ml) using the kinase screening service provided by the MRC PPU
International Centre for Kinase Profiling at the University of Dundee (S1 Table).
TbKKT19 biochemical assay development
The peptide substrate KKLRRTLSVA was custom synthesised by Pepceuticals Ltd. and used
for further investigation in a non-radiometric high-throughput compatible assay. Activity of
the TbKKT19 enzyme was determined by monitoring levels of ADP released during the enzy-
matic reaction using the commercially available ADP Hunter Plus kit (DiscoverX).
Development of the TbKKT19 assay was carried out in black, low-volume, 384-well plates
(Greiner) at room temperature (~23˚C). Enzyme linearity was assessed in a 10 minute end-
point assay with varying TbKKT19 concentrations (0–20 nM), 200 μM ATP and 200 μM pep-
tide substrate KKLRRTLSVA (‘KKL’ peptide).
Assays to determine the apparent Michaelis constants (Kmapp) for the ATP and the ‘KKL’
peptide were carried out in 8 μl reaction volumes containing 5 nM recombinant TbKKT19
prepared in the proprietary ADP Hunter buffer (pH 7.4) supplemented with 1 mM dithio-
threitol. To determine the Kmapp of ATP, the ATP concentration was varied (0–800 μM), with
the ‘KKL’ concentration fixed at a saturating concentration of 1 mM. To determine the Kmapp
of the ‘KKL’ peptide, the ‘KKL’ concentration was varied (0–800 μM), with the ATP concentra-
tion fixed at a saturating concentration of 600 μM. Detection of ADP formation was carried
out by the addition of 4 μl ADP Hunter kit reagent A, followed by the addition of 8 μl ADP
Hunter kit reagent B to each assay well. The ADP Hunter signal was allowed to develop for 30
min before the fluorescence intensity (FI) of each well was read using a PheraStar plate reader
(BMG) (Excitation 540 nm; Emission 590 nm). Assays were monitored over time (0–60 min),
with linear reaction rates at each substrate concentration determined. Rate versus substrate
concentration data were fitted to the Michaelis-Menten equation using GraFit (Erithacus
Software).
Trypanosoma brucei KKT19 inhibitors
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TbKKT19 hit identification
The TbKKT19 high throughput screen was performed using our in-house kinase-relevant
compound collection, containing 6,624 compounds [18]. All library compounds were solubi-
lized in 100% DMSO to a concentration of 10 mM.
Single point inhibition assays were carried out at room temperature (~23 ˚C) in black, low-
volume, 384-well plates (Greiner). Each assay was performed in an 8 μl reaction volume con-
taining ADP Hunter buffer (pH 7.4), 1 mM dithiothreitol, 5 nM TbKKT19, 80 μM ATP,
100 μM ‘KKL’ peptide, and 30 μM test compound.
Test compounds (24 nl in DMSO) were transferred to assay plates using an ECHO 550
acoustic dispenser (Labcyte). DMSO was added to 0% inhibition control wells, with stauros-
porine added to 100% inhibition control wells (to a final assay concentration of 30 μM). Assays
were performed by adding 4 μl buffer with enzyme to all assay plates before the reaction was
initiated with the addition of a 4 μl substrate mix containing ATP and ‘KKL’ peptide to all
wells. Following a 30 min reaction at room temperature the assay was stopped with the addi-
tion of 4 μl ADP Hunter kit reagent A, followed by the addition of 8 μl ADP Hunter kit reagent
B. The ADP Hunter signal was allowed to develop for 30 min before the FI of each well was
read using a PheraStar plate reader (BMG) (Excitation 540 nm; Emission 590 nm). All liquid
dispensing steps were carried out using a Thermo Scientific Multidrop dispenser (Matrix).
ActivityBase from IDBS was used for data processing and analysis. Test compound data
were normalised to 0% inhibition and 100% inhibition control wells on each plate, with com-
pounds designated as hits if the % inhibition at 30 μM was >35%.
To generate IC50 data for TbKKT19 hit compounds, 10-point inhibitor curves were pre-
pared in 384-well assay plates using an ECHO 550 acoustic dispenser (Labcyte). Following
preparation of the inhibitor curves, assays were carried out using the ADP Hunter assay as
described above.
ActivityBase from IDBS was again used for data processing and analysis. All IC50 curve fit-
ting was undertaken using ActivityBase XE from IDBS. A four-parameter logistic dose-
response curve fit was utilized with prefit used for all four parameters.
TbKKT19 counterscreen
As described above, 10-point inhibitor curves were prepared in 384-well plates using an
ECHO 550 acoustic dispenser (Labcyte). Counterscreen assays, to identify any compounds
inhibiting the ADP Hunter detection components rather than TbKKT19, were carried out by
adding 8 μl of 24 μM ADP, prepared in ADP Hunter buffer (pH 7.4) containing 1 mM dithio-
threitol, to all wells, with the exception of the 100% effect control wells, to which 8 μl buffer
only was added.
Following a 30 min incubation at room temperature (~23˚C), detection of ADP levels using
the ADP Hunter kit was carried out as previously described. All liquid dispensing steps were
carried out using a Thermo Scientific Multidrop dispenser (Matrix).
Data processing and analysis was performed using ActivityBase from IDBS as described
above.
Kinase-related screening set
The screening set contains 6,624 compounds containing a pharmacophore that could interact
with the hinge in the ATP binding site based on principles laid out in [18]. For the compounds
in the screening library a set of molecular properties comprising molecular weight (MW),
hydrogen bond acceptors and donors count (HBA, HBD), rotatable bonds count (Rb), aro-
matic rings count (Ar), number of heavy atoms and AlogP were calculated using BIOVIA
Trypanosoma brucei KKT19 inhibitors
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Pipeline Pilot. To evaluate the scaffold distribution, compounds were clustered within Pipeline
Pilot using their Bemis-Murcko assembly representation [19]. The clustering was carried out
using FCFP4 as molecular descriptors and Tanimoto similarity 0.4 as maxim distance from
cluster seed.
TbKKT19 modelling
Homology model. The TbKKT19 sequence was downloaded from the NCBI database
(accession code: XP_829304.1—see SI) and was used to query the PDB using “BLAST” as
implemented in the NCBI blastp suite (https://blast.ncbi.nlm.nih.gov/) to identify suitable
template structures to build the TbKKT19 model. The structure of the human cdc2-like kinase
1 (hCLK1) was selected as template. An alignment between the target sequence TbKKT19 and
the sequence extracted from the hCLK1 structure was generated using Schro¨dinger Prime and
manually curated. The optimised sequence alignment was used to build the homology model
using the knowledge-based method in Prime. Model refinement was performed by Molecular
Dynamics using Schro¨dinger Desmond.
Hit compounds docking. The three-dimensional structures of the hits were built in
Schro¨dinger Maestro, minimized with the OPLS3 force field [20] and docked in the catalytic
site of the TbKKT19 model using Schro¨dinger GLIDE-SP.
Results
Enzymatic characterisation of TbKKT19
Recombinant, His-tagged, full-length TbKKT19 protein was produced (S1 Fig) and a panel of
putative kinase substrates tested to identify a suitable peptide phosphorylated by TbKKT19
(Fig 1A and S1 Table). On the basis of its availability in the laboratory, KKLRRTLSVA (‘KKL’
peptide) was selected for further investigation. Using an assay that measures ADP production,
‘KKL’ peptide was confirmed to be phosphorylated by TbKKT19 (Fig 1B) and was used as a
peptide substrate in biochemical TbKKT19 assays. In addition, it was also noted that ADP for-
mation could be detected in the absence of the ‘KKL’ peptide (Fig 1C), which may indicate
autophosphorylation of the enzyme. Alternatively TbKKT19 may display intrinsic ATPase
activity in the absence of peptide substrate, a feature previously observed in other CMGC
kinases [21, 22]. For future assay development a concentration of 5 nM TbKKT19 was selected,
as ADP formation in the absence of ‘KKL’ peptide could not be detected using this enzyme
concentration, whereas phosphorylation of the ‘KKL’ peptide gave a robust and measurable
assay signal.
Using the ‘KKL’ peptide as a substrate, the TbKKT19 enzyme was characterised and assay
conditions optimised to ensure appropriate inhibitor screening conditions were used. This
involved determining the optimal enzyme concentration, assessing assay linearity with respect
to time, and determining apparent Michaelis constants (Kmapp) for the substrates (Fig 2). The
ATP and ‘KKL’ peptide Kmapp values were determined to be 102 μM (95% CI 87–117 μM)
and 179 μM (95% CI 150–208 μM) respectively. Pharmacological validation of the assay was
achieved using both the pan-kinase inhibitor staurosporine and the TbKKT10 (TbCLK1)
inhibitor hypothemycin [13]. Staurosporine and hypothemycin inhibited TbKKT19 with IC50
values of 288 nM (95% CI 190–386 nM) and 65 nM (95% CI 50–80 nM) respectively (Fig 3,
closed circles). In addition, when the ATP concentration was increased 10-fold from 80 μM to
800 μM, 5 to 6-fold shifts in these IC50 values were observed (1.68 μM (95% CI 0.99–2.37 μM)
and 328 nM (95% CI 267–389 nM) for staurosporine and hypothemycin respectively), indica-
tive of ATP competitive binding (Fig 3, open circles).
Trypanosoma brucei KKT19 inhibitors
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TbKKT19 hit discovery
For high-throughput screening a non-biased approach was taken, with screening concentra-
tions of 80 μM ATP and 100 μM ‘KKL’ peptide selected (i.e. substrate concentrations slightly
below their respective Kmapp, allowing inhibitors with any inhibition modality to be identified).
The screen was carried out with a kinase-relevant library of 6,624 compounds, characterised
by the presence of a pharmacophore that could interact with the hinge motif in the ATP bind-
ing site. All compounds are Lipinski rule-of-five compliant [23] and Table 1 shows the mean
values of the calculated molecular parameters; the mean values are well below the Lipinski val-
ues, allowing for further development. The library is chemically diverse and includes 957 clus-
ters and 969 singletons. The largest cluster contains 191 analogues whilst on average there are
6 molecules in each cluster. Examples of the most populated scaffolds are reported in S2 Fig.
The library was screened in single replicate at a concentration of 30 μM. To assess the robust-
ness and reproducibility of the assay and the quality of the hit discovery campaign, various cri-
teria were assessed following completion of the primary screen. These data reveal a high
quality screening campaign, with a mean Z0 [24] of 0.88 ± 0.03 and a mean signal to back-
ground ratio of 2.69 ± 0.12.
Fig 1. TbKKT19 substrate search. (A) A panel of 41 peptides and 3 proteins (see S1 Table for details) were screened as possible substrates of TbKKT19 in a
radiometric kinase assay performed by the MRC PPU International Centre for Kinase Profiling at the University of Dundee (data shown as mean counts per minute
above background (CPM) of two technical replicates). (B) Confirmation of peptide substrate activity using ADP Hunter Plus assay kit (DiscoverX). The activity of
various TbKKT19 concentrations monitored over time using 200 μM KKLRRTLSVA (peptide 8 in panel A) and 200 μM ATP (data points are n = 1). (C) Activity of
various TbKKT19 concentrations monitored over time in the presence of 200 μM ATP revealed ADP formation can be detected over time in the absence of ‘KKL’
peptide substrate (data points are n = 1). In panels (B) and (C) TbKKT19 concentrations are 175 nM (open circles), 88 nM (closed circles), 44 nM (open squares), 22
nM (closed squares), 11 nM (open triangles), 5.5 nM (closed triangles), 2.7 nM (open diamonds) and 0 nM (closed diamonds).
https://doi.org/10.1371/journal.pone.0217828.g001
Trypanosoma brucei KKT19 inhibitors
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Hit compounds were identified by applying an arbitrary threshold cut-off of 35% inhibition
with 31 compounds from the kinase library meeting this criteria (0.46% hit rate) (Fig 4A). Hit
compounds were cherry picked and retested as 10-point dose response curves in the TbKKT19
assay to determine IC50 values (potencies in the range of 9.8–100 μM determined) (Fig 4B). In
addition, hit compounds were also tested in a counterscreen assay to exclude compounds that
inhibit the ADP Hunter assay technology. Following this assessment only 8 confirmed kinase
library hits remained (Fig 4C), corresponding to a final hit rate of 0.12%.
Two of the most potent hits (compound 1 and compound 2; Fig 5) returned IC50 values of
18.9 μM (95% CI 16.5–21.6 μM) and 14.9 μM (95% CI 14.5–15.4 μM) respectively. Both com-
pounds were repurchased and reconfirmed as hits in the TbKKT19 biochemical assay, how-
ever, due to their weak potency against the TbKKT19 enzyme, no meaningful T. brucei cell-
based data could be generated for these compounds.
Fig 2. TbKKT19 assay development summary. (A) Linearity of the TbKKT19 assay with respect to enzyme concentration. Data are shown as mean FI ± SD (n = 3
technical replicates). (B) ATP Kmapp determination in the presence of a saturating concentration of 1 mM ‘KKL’ peptide. Data are shown as rate ± SE of linear fit (rates
determined from n = 2 technical replicates). (C) ‘KKL’ peptide Kmapp determination in the presence of a saturating concentration of 600 μM ATP. Data are shown as
rate ± SE of linear fit (rates determined from n = 2 technical replicates). (D) Assay linearity with respect to time under the final assay screening conditions of 5 nM
TbKKT19, 100 μM ‘KKL’ peptide and 80 μM ATP either with (open circles) or without (closed circles) 30 μM staurosporine. Data are shown as mean FI ± SD (n = 3
technical replicates).
https://doi.org/10.1371/journal.pone.0217828.g002
Trypanosoma brucei KKT19 inhibitors
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TbKKT19 homology model
To understand the binding mode of our hit compounds and to try to account for the low hit
rate observed for this kinetochore kinase, a TbKKT19 homology model was generated. The
TbKKT19 sequence used to identify suitable 3D template structures using NCBI BLAST is
shown in S3 Fig. Several human cdc2-like kinase (CLK) structures (e.g. hCLK3—PDB codes
2eu9; 2exe, 2wu6, 2wu7h—sequence identity 34%; hCLK1—PDB code: 1z57—sequence
Fig 3. Staurosporine and hypothemycin inhibit TbKKT19. (A) Staurosporine inhibits TbKKT19 with an IC50 of 288 nM (95% CI of best fit 190–386 nM) in the
presence of 80 μM ATP (closed circles) and 1.68 μM (95% CI of best fit 0.99–2.37 μM) in the presence of 800 μM ATP (open circles). (B) Hypothemycin inhibits the
TbKKT19 enzyme with an IC50 of 65 nM (95% CI of best fit 50–80 nM) in the presence of 80 μM ATP (closed circles) and 328 nM (95% CI of best fit 267–389 nM) in
the presence of 800 μM ATP (open circles). The 5.8-fold and 5.0-fold shifts in potency for staurosporine and hypothemycin respectively with increasing ATP
concentrations are consistent with ATP competitive inhibition. All data points presented as mean % inhibition ± SD (n = 3 technical replicates).
https://doi.org/10.1371/journal.pone.0217828.g003
Table 1. Calculated properties for kinase-relevant compound library.
Molecular property Mean value
Molecular weight 320.35
HBA count 4.1
HBD count 1.2
Heavy atoms count 23
Rotatable bonds count 3.9
Number of aromatic rings 2.7
AlogP 2.67
https://doi.org/10.1371/journal.pone.0217828.t001
Trypanosoma brucei KKT19 inhibitors
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identity 34%; hCLK2—PDB code 3nr9—sequence identity 34%) were identified as suitable
template structures for homology modelling. After inspection of the highly homologous struc-
tures only structures containing small molecule ligands were considered. Apo structures (e.g.
PDB code 2eu9), structure with missing N lobe (PDB code 2exe) or structures with com-
pounds not matching the hinge pharmacophore [25] (e.g. PDB code 2vag) were excluded.
Fig 4. TbKKT19 hit discovery summary. (A) Frequency distribution of compound percentage inhibition values. An arbitrary hit identification cut-off of 35%
inhibition identified 31 putative hit molecules out of 6,624 molecules screened (0.46% hit rate). (B) Correlation between two independent pIC50 (−log IC50 (M))
determinations for each of the 31 hit compounds. Black circles represent test compounds, grey circle is staurosporine control. Dashed line is line of equipotence; solid
line is linear regression of these data with a correlation coefficient of 0.93. (C) Correlation between mean TbKKT19 pIC50 from two independent determinations and
the pIC50 measured in an ADP Hunter technology interference counterscreen. Black circles represent true TbKKT19 hits (inactive in counterscreen assay), grey circles
represent compounds displaying technology interference. Dashed line is line of equipotence.
https://doi.org/10.1371/journal.pone.0217828.g004
Trypanosoma brucei KKT19 inhibitors
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Finally, the structure of the human cdc2-like kinase 1 (hCLK1) complexed with 10Z-Hyme-
nialdisine [PDB code: 1z57] [26] was selected as a template to build the TbKKT19 model.
An alignment between the target sequence TbKKT19 and the sequence extracted from the
hCLK1 structure (Fig 6A) was generated. Despite a relatively low level of sequence conserva-
tion, kinases are characterised by a high degree of structural similarity. The alignment was
manually curated to remove gaps / insertions from secondary structural elements and to
ensure that the typical kinase sequence motifs important for catalysis and regulation were cor-
rectly aligned. A homology model for TbKKT19 was then generated based on hCLK1 structure
using the optimised sequence alignment. The homology model was further optimised by
energy minimisation and further validated by molecular dynamics (MD). An MD simulation
of 100 ns showed that the system is well equilibrated and the template ligand is stably bound to
the ATP pocket interacting with the hinge and the conserved catalytic Lys and Asp of the DLG
motif (S4 Fig).
Compound 1 and compound 2 binding mode
Both validated hit compounds (Fig 5) contain well-characterised hinge-binder chemical scaf-
folds. For instance, compound 2 contains an indazole ring that is also present in the kinase
inhibitor entrectinib, currently in Phase II against NTRK/ROS1/ALK driven tumours, whereas
the trans-3-ethylideneindolin-2-one group in compound 1 is also the hinge binding moiety in
sunitinib, an inhibitor of receptor tyrosine kinases, currently on the market for the treatment
of renal cell carcinoma and gastrointestinal stromal tumours.
Fig 5. Compound 1 and compound 2 inhibit TbKKT19. (A) Compound 1 and (B) compound 2 inhibit TbKKT19 with IC50 values of 18.9 μM (95% CI of best fit
16.5–21.6 μM) and 14.9 μM (95% CI of best fit 14.5–15.4 μM) respectively when screened using final assay conditions of 5 nM TbKKT19, 100 μM ‘KKL’ peptide and
80 μM ATP. All data points shown (n = 2 biological replicates).
https://doi.org/10.1371/journal.pone.0217828.g005
Trypanosoma brucei KKT19 inhibitors
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The binding mode for both compounds in TbKKT19 was investigated. The docking model
for compound 1 (Fig 7A) is consistent with the mode of binding of sunitinib in different
kinases (e.g. KIT, CDK2). The indolinone scaffold establishes two hydrogen bond interactions
with the hinge motif of KKT19. One between the Tyr112 backbone NH and the carbonyl oxy-
gen of the ligand and one between the Pro110 backbone carbonyl oxygen and the lactam NH.
The phenyl ring of the indolinone moiety faces the gatekeeper residue Met 109. The double
bond in compound 1 is trans whereas the equivalent bond in sunitinib is cis. That results in
compound 1 developing into the ATP binding site following a different vector and placing the
furan ring in the sugar subpocket. The indazole scaffold of compound 2 also occupies the ade-
nine pocket of the ATP binding site and interacts with the Tyr112 backbone NH in the hinge
(Fig 7B). The di-o-Cl-phenyl moiety is positioned underneath the Gly-rich loop establishing
π-stacking with Phe40.
Analysis of low hit rate
As the low hit-rate in the kinase-relevant compound library screen was unexpected we looked
for possible explanations. An analysis of the TbKKT19 sequence highlighted a number of
unusual features (Fig 6). The beginning of the kinase activation loop is normally characterised
by the DFG motif. The aspartate residue is crucial for the binding of divalent cations that coor-
dinate the ATP phosphate groups whereas the phenylalanine of the DFG motif plays an impor-
tant role in regulatory mechanisms and catalytic efficiency as it is part of the regulatory
hydrophobic spine (R-spine), a highly conserved spatial motif comprising four non-consecu-
tive hydrophobic residues [27]. The structural assembly of the R-spine is a requirement for
activated kinases. Hence, formation of the R-spine is highly regulated and typically requires
phosphorylation of the activation loop. Together with the catalytic hydrophobic spine (C-
spine) and the gatekeeper residue, the R-spine is functionally relevant [28]. In TbKKT19 the
activation loop starts with a DLG motif where the phenylalanine residue is replaced by a leu-
cine. We hypothesised that the change in the hydrophobic spine amino-acid composition
Fig 6. Sequence alignment and TbKKT19 homology model. In yellow, the xGxGxxGx motif of the Gly-rich loop, in light green the xAVK motif of the highly
conserved catalytic Lys, in teal the α-C helix with the conserved catalytic Glu, in blue the hinge region starting with the gatekeeper residue, in magenta the HxD motif,
in brown the DxG motif and in dark green the xPE motif. In orange the β-hairpin insertion and in red the LAMMER motif typical of the cdc2-like kinase family.
https://doi.org/10.1371/journal.pone.0217828.g006
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could have an impact on ATP Km. Kinases characterised by a low ATP Km value can be diffi-
cult to target as small molecule compounds will have to be very potent to be able to compete
with cellular ATP. However, we determined that TbKKT19 has a relatively high ATP Kmapp
(102 μM), indicating that it should be possible to identify compounds capable of competing
for the ATP binding site. The end of the TbKKT19 activation loop is characterised by an SPE
motif instead of the more common APE motif. The APE motif is important for catalysis as it
interacts with the αF-helix stabilising the activation loop. The replacement of the alanine or
proline residues of the APE motif is however not predicted to disrupt this interaction.
The TbKKT19 sequence also presents a HTD motif instead of the common HRD motif.
The HRD motif is a highly conserved motif in the catalytic loop, it is a key regulatory and sub-
strate binding element as the histidine residue is also part of the hydrophobic spine and the
aspartate is involved in the phospho transfer step [29]. The HRD replacement by a HTD motif
is common in all members of the CLK family and does not seem to have an impact on the cata-
lytic efficiency of the kinase [26].
The TbKKT19 hinge region comprises the motif MPKYGPC. The presence of the two pro-
line residues in position 1 and 5 relative to the gatekeeper residue Met109 (GK+1 and GK+5)
Fig 7. Docking study results. (A) Binding mode and 2D interaction diagram for compound 1 and (B) binding mode and 2D interaction diagram for compound 2.
Ligand is characterised by yellow carbon atoms. Red arrows/dashed lines indicate hydrogen bonding interactions, green line indicate π-stacking.
https://doi.org/10.1371/journal.pone.0217828.g007
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was investigated to verify the impact on the hinge pharmacophore. The presence of Pro resi-
dues can alter the recognition pattern between the hinge and the ligand as the unique Pro
geometry changes the orientation of the backbone features interacting with the ligand. A
typical example is PIM1 where the presence of a proline in position GK+3 removes the key
hydrogen bond acceptor feature from the hinge resulting in an unconventional kinase hinge
pharmacophore. A 100 ns dynamic simulation was carried out showing that the proline resi-
dues in the TbKKT19 hinge do not alter the recognition motif at the hinge. This is also consis-
tent with the hinge geometry observed in other kinase structures with one Pro residues either
in position GK+1 (e.g. MET) or position GK+5 (e.g. CK1).
Finally, an analysis of the TbKKT19 sequence in relation to the hCLK1 structure used as
template shows that the TbKKT19 sequence matches a number of long insertions typical of the
CLK family. In particular, residues 165–183 (Fig 6) are mapping to an extended β-hairpin at
the top of the C-terminal lobe in the template structure. Residues 251–283 map onto a long
insertion at the bottom of the C-terminal domain. In the CLK1 structure this insertion renders
the αG-helix that includes part of the LAMMER motif that characterises the CLK family, sol-
vent inaccessible. The LAMMER motif seems to be only partially conserved in TbKKT19 (the
EHLAMMERILG in human is EHLHLMEKTLG in T. brucei). These elements are important
in the recognition of substrate but should not interfere with the binding of small molecules at
the ATP site. Altogether, none of the TbKKT19 specific sequence features appear to explain
the unexpectedly low hit-rate.
Discussion
KKT19 was previously identified as an unconventional kinetochore kinase in T. brucei [5].
Kinetic characterisation of this protein revealed it was enzymatically active as a kinase, with a
substrate specificity profile similar to other reported CLK kinases (consensus sequence
R-X-X-S) [26, 30, 31]. In addition, TbKKT19 was inhibited by the pan-kinase inhibitor staur-
osporine as well as hypothemycin, a natural product known to inhibit kinases with a cysteine
residue before the DXG motif [13], as seen for TbKKT19. Hypothemycin was previously
shown to inhibit TbKKT10 and the IC50 generated here for TbKKT19, in presence of 80 μM
ATP, as well as the ATP-competitive profile, are highly comparable to the data published for
TbKKT10 (IC50 = 150 nM when assayed using 100 μM ATP [13]). This is not unexpected as
both enzymes are closely related, and may well have redundant functions, it is therefore reas-
suring from a drug discovery perspective that dual inhibition of TbKKT10 and TbKKT19 is
possible.
Despite appearing to function as a typical protein kinase and showing a pharmacological
profile consistent with other kinases of the same family, a high-throughput screen of a kinase-
relevant library yielded a very low hit rate. This result was unexpected as this library is com-
posed of compounds with scaffolds designed to bind the ATP site of kinases and previous
screens using a similar compound set with other kinases yielded higher hit rates (for example,
the T. brucei GSK3 and Leishmania CRK3 kinases returned hit rates of 12.8% and 2.2% respec-
tively) [32, 33]. The small number of TbKKT19 hit molecules that we did identify contained
known kinase hinge-binding motifs.
In the absence of a crystal structure, and to investigate the unexpectedly low hit rate further,
a homology model of TbKKT19 was generated, and docking of two key hits into the model
was consistent with other known hinge-binding compounds. TbKKT19 has a series of unusual
amino acid sequences in conserved kinase motifs, but based on the homology model none of
these should affect compound binding in the ATP-binding pocket. In conclusion, homology
modelling of this kinetoplastid kinetochore kinase could not provide any explanation for the
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low hit rates observed and the divergent pharmacology between TbKKT19 and other kinases
should be investigated further.
The few hit molecules that we identified had low potency against the enzyme. In order to
develop tool molecules for target validation or potential new drug candidates for HAT a signif-
icant amount of work will be required not only to increase potency but also to generate com-
pounds with optimal solubility, metabolic stability, oral bio-availability and CNS penetration.
While the homology model will be useful to guide such efforts ideally a crystal structure is gen-
erated to facilitate this.
Supporting information
S1 Table. Substrate search peptide sequences and proteins.
(DOCX)
S1 Fig. TbKKT19 protein production. SDS-PAGE gel showing production of 91.2% pure
His-tagged, full-length TbKKT19 protein.
(DOCX)
S2 Fig. Scaffold representation in kinase-relevant compound library. Compound structures
exemplifying the chemical scaffolds in the 10 largest of the 957 clusters obtained from the
6,624 compounds in the kinase-relevant library.
(DOCX)
S3 Fig. T. brucei KKT19 sequence. The TbKKT19 sequence is shown (https://www.ncbi.nlm.
nih.gov/protein/XP_829304.1). In green are the residues that have been incorporated in the
homology model.
(DOCX)
S4 Fig. TbKKT19 molecular dynamics simulation. Interaction that the 10Z-Hymenialdisine
compounds from the hCLK1 template structure establishes in the TbKKT19 model. The per-
centage values indicate the proportion of time a specific interaction is present during an MD
simulation of 100 ns.
(DOCX)
Acknowledgments
We thank Bungo Akiyoshi for provision of the TbKKT19 plasmid and helpful discussions.
We also acknowledge the support of the Protein Production, Compound Management and
Data Management Teams within the Wellcome Centre for Anti-Infectives Research
(WCAIR).
Author Contributions
Conceptualization: Leah S. Torrie, David A. Robinson, Ian H. Gilbert, Manu De Rycker.
Data curation: Leah S. Torrie.
Formal analysis: Leah S. Torrie, Fabio Zuccotto, Manu De Rycker.
Funding acquisition: David W. Gray, Ian H. Gilbert.
Investigation: Leah S. Torrie, Fabio Zuccotto.
Methodology: Leah S. Torrie, Fabio Zuccotto.
Project administration: Leah S. Torrie, David A. Robinson, Ian H. Gilbert, Manu De Rycker.
Trypanosoma brucei KKT19 inhibitors
PLOS ONE | https://doi.org/10.1371/journal.pone.0217828 May 31, 2019 14 / 16
Supervision: David W. Gray, Ian H. Gilbert, Manu De Rycker.
Validation: Leah S. Torrie.
Visualization: Leah S. Torrie.
Writing – original draft: Leah S. Torrie, Fabio Zuccotto.
Writing – review & editing: David A. Robinson, David W. Gray, Ian H. Gilbert, Manu De
Rycker.
References
1. Monda JK, Cheeseman IM. The kinetochore-microtubule interface at a glance. J Cell Sci. 2018; 131
(16).
2. Cheeseman IM. The kinetochore. Cold Spring Harbor perspectives in biology. 2014; 6(7):a015826.
https://doi.org/10.1101/cshperspect.a015826 PMID: 24984773
3. van Hooff JJ, Tromer E, van Wijk LM, Snel B, Kops GJ. Evolutionary dynamics of the kinetochore net-
work in eukaryotes as revealed by comparative genomics. EMBO Rep. 2017; 18(9):1559–71. https://
doi.org/10.15252/embr.201744102 PMID: 28642229
4. Buscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. Lancet. 2017;
390(10110):2397–409. https://doi.org/10.1016/S0140-6736(17)31510-6 PMID: 28673422
5. Akiyoshi B, Gull K. Discovery of unconventional kinetochores in kinetoplastids. Cell. 2014; 156
(6):1247–58. https://doi.org/10.1016/j.cell.2014.01.049 PMID: 24582333
6. Nerusheva OO, Akiyoshi B. Divergent polo box domains underpin the unique kinetoplastid kinetochore.
Open Biol. 2016; 6(3).
7. Akiyoshi B. The unconventional kinetoplastid kinetochore: from discovery toward functional understand-
ing. Biochem Soc Trans. 2016; 44(5):1201–17. https://doi.org/10.1042/BST20160112 PMID: 27911702
8. Perez-Molina JA, Molina I. Chagas disease. Lancet. 2018; 391(10115):82–94. https://doi.org/10.1016/
S0140-6736(17)31612-4 PMID: 28673423
9. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018; 392(10151):951–70. https://doi.org/10.
1016/S0140-6736(18)31204-2 PMID: 30126638
10. De Rycker M, Baragana B, Duce SL, Gilbert IH. Challenges and recent progress in drug discovery for
tropical diseases. Nature. 2018; 559(7715):498–506. https://doi.org/10.1038/s41586-018-0327-4
PMID: 30046073
11. Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, et al. Recent Development of Visceral
Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. Clin Microbiol Rev. 2018; 31(4).
12. Jones NG, Thomas EB, Brown E, Dickens NJ, Hammarton TC, Mottram JC. Regulators of Trypano-
soma brucei cell cycle progression and differentiation identified using a kinome-wide RNAi screen.
PLoS pathogens. 2014; 10(1):e1003886. https://doi.org/10.1371/journal.ppat.1003886 PMID:
24453978
13. Nishino M, Choy JW, Gushwa NN, Oses-Prieto JA, Koupparis K, Burlingame AL, et al. Hypothemycin,
a fungal natural product, identifies therapeutic targets in Trypanosoma brucei [corrected]. Elife. 2013; 2:
e00712. PMID: 23853713
14. Alsford S, Turner DJ, Obado SO, Sanchez-Flores A, Glover L, Berriman M, et al. High-throughput phe-
notyping using parallel sequencing of RNA interference targets in the African trypanosome. Genome
Res. 2011; 21(6):915–24. https://doi.org/10.1101/gr.115089.110 PMID: 21363968
15. Glover L, Alsford S, Baker N, Turner DJ, Sanchez-Flores A, Hutchinson S, et al. Genome-scale RNAi
screens for high-throughput phenotyping in bloodstream-form African trypanosomes. Nat Protoc. 2015;
10(1):106–33. https://doi.org/10.1038/nprot.2015.005 PMID: 25502887
16. Mackey ZB, Koupparis K, Nishino M, McKerrow JH. High-throughput analysis of an RNAi library identi-
fies novel kinase targets in Trypanosoma brucei. Chem Biol Drug Des. 2011; 78(3):454–63. PMID:
21668652
17. Parsons M, Worthey EA, Ward PN, Mottram JC. Comparative analysis of the kinomes of three patho-
genic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Geno-
mics. 2005; 6:127. https://doi.org/10.1186/1471-2164-6-127 PMID: 16164760
18. Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J, et al. Lessons learnt from assem-
bling screening libraries for drug discovery for neglected diseases. ChemMedChem. 2008; 3(3):435–
44. PMID: 18064617
Trypanosoma brucei KKT19 inhibitors
PLOS ONE | https://doi.org/10.1371/journal.pone.0217828 May 31, 2019 15 / 16
19. Bemis GW, Murcko MA. The properties of known drugs. 1. Molecular frameworks. J Med Chem. 1996;
39(15):2887–93. https://doi.org/10.1021/jm9602928 PMID: 8709122
20. Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, et al. OPLS3: A Force Field Providing Broad
Coverage of Drug-like Small Molecules and Proteins. J Chem Theory Comput. 2016; 12(1):281–96.
https://doi.org/10.1021/acs.jctc.5b00864 PMID: 26584231
21. Chen G, Porter MD, Bristol JR, Fitzgibbon MJ, Pazhanisamy S. Kinetic mechanism of the p38-alpha
MAP kinase: phosphoryl transfer to synthetic peptides. Biochemistry. 2000; 39(8):2079–87. PMID:
10684658
22. Prowse CN, Lew J. Mechanism of activation of ERK2 by dual phosphorylation. J Biol Chem. 2001;
276(1):99–103. https://doi.org/10.1074/jbc.M008137200 PMID: 11016942
23. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to esti-
mate solubility and permeability in drug discovery and development settings. Advanced drug delivery
reviews. 2001; 46(1–3):3–26. PMID: 11259830
24. Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Valida-
tion of High Throughput Screening Assays. J Biomol Screen. 1999; 4(2):67–73. https://doi.org/10.1177/
108705719900400206 PMID: 10838414
25. Zuccotto F, Ardini E, Casale E, Angiolini M. Through the "gatekeeper door": exploiting the active kinase
conformation. J Med Chem. 2010; 53(7):2681–94. https://doi.org/10.1021/jm901443h PMID: 20000735
26. Bullock AN, Das S, Debreczeni JE, Rellos P, Fedorov O, Niesen FH, et al. Kinase domain insertions
define distinct roles of CLK kinases in SR protein phosphorylation. Structure. 2009; 17(3):352–62.
https://doi.org/10.1016/j.str.2008.12.023 PMID: 19278650
27. Taylor SS, Kornev AP. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci.
2011; 36(2):65–77. https://doi.org/10.1016/j.tibs.2010.09.006 PMID: 20971646
28. Kim J, Ahuja LG, Chao FA, Xia Y, McClendon CL, Kornev AP, et al. A dynamic hydrophobic core
orchestrates allostery in protein kinases. Science advances. 2017; 3(4):e1600663. https://doi.org/10.
1126/sciadv.1600663 PMID: 28435869
29. Zhang L, Wang JC, Hou L, Cao PR, Wu L, Zhang QS, et al. Functional Role of Histidine in the Con-
served His-x-Asp Motif in the Catalytic Core of Protein Kinases. Sci Rep. 2015; 5:10115. https://doi.org/
10.1038/srep10115 PMID: 25960268
30. Menegay HJ, Myers MP, Moeslein FM, Landreth GE. Biochemical characterization and localization of
the dual specificity kinase CLK1. J Cell Sci. 2000; 113 (Pt 18):3241–53.
31. Moeslein FM, Myers MP, Landreth GE. The CLK family kinases, CLK1 and CLK2, phosphorylate and
activate the tyrosine phosphatase, PTP-1B. J Biol Chem. 1999; 274(38):26697–704. https://doi.org/10.
1074/jbc.274.38.26697 PMID: 10480872
32. Woodland A, Grimaldi R, Luksch T, Cleghorn LA, Ojo KK, Van Voorhis WC, et al. From on-target to off-
target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their charac-
terisation as anti-Trypanosoma brucei drug discovery lead molecules. ChemMedChem. 2013; 8
(7):1127–37. PMID: 23776181
33. Cleghorn LA, Woodland A, Collie IT, Torrie LS, Norcross N, Luksch T, et al. Identification of inhibitors of
the Leishmania cdc2-related protein kinase CRK3. ChemMedChem. 2011; 6(12):2214–24. PMID:
21913331
Trypanosoma brucei KKT19 inhibitors
PLOS ONE | https://doi.org/10.1371/journal.pone.0217828 May 31, 2019 16 / 16
